Elisabeth Oelmann
Chief Tech/Sci/R&D Officer presso NUCANA PLC
Profilo
Elisabeth Oelmann holds the position of Senior VP-Medical & Clinical Development at NuCana Plc.
In her past career she occupied the position of Senior Medical Director at Kymab Ltd., Medical Director-Oncology Europe Region at PRA International LLC and Professor at Freie Universität Berlin.
Dr. Oelmann received a doctorate from the University of Münster.
Posizioni attive di Elisabeth Oelmann
Società | Posizione | Inizio |
---|---|---|
NUCANA PLC | Chief Tech/Sci/R&D Officer | 01/09/2020 |
Precedenti posizioni note di Elisabeth Oelmann
Società | Posizione | Fine |
---|---|---|
PRA International LLC
PRA International LLC Pharmaceuticals: OtherHealth Technology Part of ICON plc, PRA International LLC is a clinical research organization. The private company is based in Raleigh, NC. | Corporate Officer/Principal | - |
Freie Universität Berlin | Corporate Officer/Principal | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Chief Tech/Sci/R&D Officer | - |
Formazione di Elisabeth Oelmann
University of Münster | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
NUCANA PLC | Health Technology |
Aziende private | 2 |
---|---|
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
PRA International LLC
PRA International LLC Pharmaceuticals: OtherHealth Technology Part of ICON plc, PRA International LLC is a clinical research organization. The private company is based in Raleigh, NC. | Health Technology |